Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Milk protein may shield obese moms from anemia

NCT ID NCT04810546

Prevention Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking a daily supplement of lactoferrin (a protein found in milk) can help prevent iron deficiency anemia in pregnant women with obesity. 23 women at risk for anemia took part from mid-pregnancy through labor. The main goal was to see if the approach was practical and acceptable, with early signs of improved iron levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Feb 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * naturally conceived, single pregnancy * at risk of IDA \[Hb 11.0 - 12.0 g/dL (first trimester)/10.5 - 11.5 g/dL (second trimester) for non-Black women and 10.2 - 11.2 g/dL (first trimester)/9.7 -- 10.7 g/dL (second trimester) for Black women\]42 based on new OB complete blood count (CBC) results obtained from the EMR * 18 - 45 years old * pre-conception BMI ≥ 30.0 kg/m2 \[based on measured height in EMR and recent pre-conception weight (within 3 months of pregnancy) from EMR if available or self-reported\]; \< 20 WG * fluency in English to provide consent and complete study procedures; * ability to provide consent * ownership of a smartphone (currently more than 90% of our patient population at the Center for Women's Health) Exclusion Criteria: * birth, or other pregnancy in the previous 12 months * IDA requiring high dose supplemental iron * allergy to milk proteins or wheat * vegan (due to content of the supplements) * recent blood transfusion * previously diagnosed type 1 or type 2 diabetes * autoimmune disorder (e.g., rheumatoid arthritis) * inflammatory bowel disease * premature rupture of membranes or chorioamnionitis * previous spontaneous preterm birth * current bacterial or viral infection * history of bariatric surgery * malabsorptive disease * current hyperemesis * current eating disorder * hematologic disorder or trait carrier (e.g., hemochromatosis, β-thalassemia) * current tobacco, alcohol or illicit drug use (including marijuana) * regular use of medications that may interfere with nutrient absorption * unstable housing, first trimester PHQ-9 score \> 10, and/or a recent traumatic event (e.g., death of a significant other or parent) may make it difficult to comply with the interventions, hence these women will also be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Iron-deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

iron deficiency anemia Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Iron-deficiency Obesity Pregnancy anemia

Contacts and locations

Locations

  • University of Illinois at Chicago

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.